{"entity":{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","aka":[],"tldr":"Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer.","summary":"Arsenal Biosciences, based in South San Francisco, is a programmable CAR-T company that uses logic gates so its cells fire only when two tumour proteins are present, and its AB-2100 is in phase 1/2 for kidney cancer. AB-2100 combines a synthetic AND gate requiring both PSMA and CA9, shRNA armouring against suppression in the tumour microenvironment and a synthetic pathway activator, and is being tested in clear-cell renal cell carcinoma after immunotherapy and VEGF therapy in trial NCT06245915; AB-1015 targets ovarian cancer, and the company raised 325 million dollars with Regeneron and Bristol Myers Squibb participating. OnCo links it to renal and ovarian cancer, to armoured and logic-gated CARs and logic-gated therapeutics, and to PSMA as a target. Whether logic gating solves the on-target, off-tumour problem that has stalled solid-tumour CAR-T is the question its trial will test.","asOf":"2026-09-04","links":[{"label":"AB-2100 trial","url":"https://clinicaltrials.gov/study/NCT06245915"},{"label":"PICI news: ArsenalBio","url":"https://www.parkerici.org/?s=arsenalbio"}],"tags":["frontier"],"related":[],"cancers":["rcc","ovarian"],"sections":["cell-therapy"],"technologies":["armored-car","car-t"],"targets":["psma"],"drugs":[],"companies":["bms","regeneron"],"institutions":["parker-institute"],"pathways":[],"terms":[],"trials":["nct06245915","nct07285694"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The Parker Institute for Cancer Immunotherapy's own news pages describe ArsenalBio as a company it launched in 2019, with a founders' interview on the institute's site."],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://arsenalbio.com","investors":["arch-venture-partners"],"funding":[]},"route":"/companies/arsenal-bio/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"company":[{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}],"institution":[{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"}],"trial":[{"id":"nct06245915","kind":"trial","name":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","route":"/trials/nct06245915/"},{"id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","route":"/trials/nct07285694/"}]}}